Marinus Pharmaceuticals Inc (MRNS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Marinus Pharmaceuticals Inc (MRNS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8011
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Marinus Pharmaceuticals Inc (Marinus) is a clinical stage biopharmaceutical company that manufactures and commercializes therapeutics for the treatment of epilepsy, neuropsychiatric disorders and others diseases. The company’s pipeline product comprise ganaxolone is a CNS-selective GABAA modulator, which has being developed in three different dose forms such as IV, capsule and liquid that is intended to maximize therapeutic reach to adult and pediatric patients in both acute and chronic care settings. Its Ganaxolone product has being evaluated in clinical trials for the treatment of pediatric genetic orphan epilepsies, behaviours in fragile x syndrome, and status epilepticus. Marinus is headquartered in Radnor, Pennsylvania, the US.

Marinus Pharmaceuticals Inc (MRNS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Marinus Pharma Raises US$21 Million In Series C Financing 11
Marinus Pharmaceuticals Raises USD11.43 in Venture Financing 13
Marinus Pharma Raises USD21.8 Million in Venture Financing 14
Licensing Agreements 15
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 15
CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 16
Equity Offering 17
Marinus Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 17
Marinus Pharma Raises USD40.3 Million in Public Offering of Shares 18
Marinus Pharma Raises USD30 Million in Public Offering of Shares 20
Marinus Pharma Files Registration Statement for Public Offering of Shares for up to USD35 Million 21
Marinus Pharma Completes IPO 22
Marinus Pharmaceuticals Inc – Key Competitors 24
Marinus Pharmaceuticals Inc – Key Employees 25
Marinus Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 02, 2018: Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results 27
May 02, 2018: Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results 29
Mar 06, 2018: Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results 30
Oct 31, 2017: Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results 32
Aug 01, 2017: Marinus Pharmaceuticals Reports Second Quarter 2017 Financial Results 34
Mar 13, 2017: Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results 35
Corporate Communications 36
Apr 11, 2017: Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer 36
Feb 01, 2017: Marinus Appoints Michael R. Dougherty to its Board of Directors 37
Product Approvals 38
Jun 29, 2017: FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder 38
Jan 03, 2017: Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome 39
Clinical Trials 40
Sep 11, 2017: Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone 40
Aug 01, 2017: Marinus Pharmaceuticals Announces Update on Ganaxolone 42
Jun 27, 2017: Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression 43
Apr 18, 2017: Marinus to present Ganaxolone DATA at American academy of neurology annual meeting 44
Apr 10, 2017: Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference 45
Feb 14, 2017: Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model 46
Jan 23, 2017: Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder 47
Jan 05, 2017: Marinus Provides Business Outlook for 2017 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Marinus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marinus Pharma Raises US$21 Million In Series C Financing 11
Marinus Pharmaceuticals Raises USD11.43 in Venture Financing 13
Marinus Pharma Raises USD21.8 Million in Venture Financing 14
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 15
CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 16
Marinus Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 17
Marinus Pharma Raises USD40.3 Million in Public Offering of Shares 18
Marinus Pharma Raises USD30 Million in Public Offering of Shares 20
Marinus Pharma Files Registration Statement for Public Offering of Shares for up to USD35 Million 21
Marinus Pharma Completes IPO 22
Marinus Pharmaceuticals Inc, Key Competitors 24
Marinus Pharmaceuticals Inc, Key Employees 25

List of Figures
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Marinus Pharmaceuticals Inc (MRNS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • LIncoln Electric Holdings Inc:企業のM&A・事業提携・投資動向
    LIncoln Electric Holdings Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LIncoln Electric Holdings Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Aspyrian Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Aspyrian Therapeutics Inc (Aspyrian Therapeutics) is a biotechnology company which develops precision targeted medicines to handle both the primary tumor and systemic disease. Its lead pipeline product, RM-1929, is under development for the treatment of different cancer types, including canc …
  • Clean Harbors, Inc. (CLH):企業の財務・戦略的SWOT分析
    Clean Harbors, Inc. (CLH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • EndoChoice Inc:医療機器:M&Aディール及び事業提携情報
    Summary EndoChoice Inc (EndoChoice), a subsidiary of Boston Scientific Corp is a medical device company that develops and commercializes medical devices, diagnostic equipment, infection control products and endoscopic imaging systems. The company’s infection control products comprise biopsy valves, …
  • Semiconductor Manufacturing International Corporation:企業の戦略・SWOT・財務情報
    Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report Summary Semiconductor Manufacturing International Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Sosei Group Corp (4565):製薬・医療:M&Aディール及び事業提携情報
    Summary Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal agent, administered as a muco-adhe …
  • Philip Morris International Inc.:企業の戦略・SWOT・財務情報
    Philip Morris International Inc. - Strategy, SWOT and Corporate Finance Report Summary Philip Morris International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Covalon Technologies Ltd (COV)-医療機器分野:企業M&A・提携分析
    Summary Covalon Technologies Ltd (Covalon) is a researcher, developer and commercialization of medical devices and healthcare technologies. The company offers advanced wound solutions, infection prevention products and perioperative care products. Covalon offers wound care products such as collagen …
  • Lazard Ltd:企業の戦略・SWOT・財務分析
    Lazard Ltd - Strategy, SWOT and Corporate Finance Report Summary Lazard Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • UOB Private Banking:企業の戦略・SWOT・財務情報
    UOB Private Banking - Strategy, SWOT and Corporate Finance Report Summary UOB Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Coherent Inc (COHR):企業の財務・戦略的SWOT分析
    Coherent Inc (COHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Genomic Expression Inc:企業の製品パイプライン分析
    Summary Genomic Expression Inc (Genomic Expression) is a provider of cancer diagnostics services that offers treatments for cancer diagnostics for personalized medicine. The company offers products such as sample sequencing sample preparation kit and analytical platform. Its sequencing platform prov …
  • Oman United Insurance Co. Saog:企業の戦略・SWOT・財務分析
    Oman United Insurance Co. Saog - Strategy, SWOT and Corporate Finance Report Summary Oman United Insurance Co. Saog - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Severn Trent Plc:企業の戦略・SWOT・財務情報
    Severn Trent Plc - Strategy, SWOT and Corporate Finance Report Summary Severn Trent Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Advanced Accelerator Applications SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • Sumitomo Corp (8053):石油・ガス:M&Aディール及び事業提携情報
    Summary Sumitomo Corp (Sumitomo) is a multifaceted business enterprise. It operates various businesses such as metal products, transportation, construction systems, infrastructure, media, network & lifestyle retail, general products, real estate, financial services, logistics, mineral resources and …
  • Southern California Edison Co:企業の発電所・SWOT分析2018
    Southern California Edison Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Boule Diagnostics AB (BOUL)-医療機器分野:企業M&A・提携分析
    Summary Boule Diagnostics AB (Boule) is a medical device company that develops, manufactures and markets blood counting systems. The company provides systems and consumer products for complete blood counts to non-institutional healthcare. Its products include blood cell counter and instruments, reag …
  • Nu Skin Enterprises, Inc.:企業の戦略・SWOT・財務情報
    Nu Skin Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nu Skin Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sophia Genetics SA:医療機器:M&Aディール及び事業提携情報
    Summary Sophia Genetics SA (Sophia Genetics) is a health tech company that provides technological solutions such as SOPHiA Artificial Intelligence for clinical genomics and next generation sequencing (NGS) data analysis. The company also provides dry lab, bundle solution, and integrated diagnostic s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆